SRL
VRDN icon

Scientech Research LLC’s Viridian Therapeutics VRDN Stock Holding History

Scientech Research LLC’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65,080
Closed -$1.27M – 569
2026
Q1 		$1.27M Buy
+65,080
New +$1.93M 1.06% 6
2025
Q1 		– Sell
-20,143
Closed -$386K – 837
2024
Q4 		$386K Sell
20,143
-6,717
-25% -$146K 0.11% 367
2024
Q3 		$611K Buy
+26,860
New +$439K 0.12% 330

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Scientech Research LLC's VRDN Position: Q2 2026 in Review

Scientech Research LLC sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 65,080 shares — an estimated $1.27M sold.

Scientech Research LLC first reported a position in VRDN in Q3 2024 and held it in 3 quarters. The position peaked at $1.27M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Scientech Research LLC reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Scientech Research LLC sold 65,080 Viridian Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Scientech Research LLC first reported a position in Viridian Therapeutics in Q3 2024 and held it in 3 quarters.
  • Scientech Research LLC's Viridian Therapeutics position peaked at $1.27M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.